Management Change/Compensation - Form 8-K

Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

On April 10, 2024, Omega Therapeutics, Inc. (the "Company") and Joshua Reed, the Company's Chief Financial Officer, agreed to terminate his employment effective as of May 31, 2024 (the "Effective Date"). In connection with the termination, Mr. Reed will be entitled to receive the severance payments and benefits set forth in his employment agreement with the Company and extended exercisability of his exercisable Company stock options until the first anniversary of the Effective Date, in each case, subject to his entering into a separation agreement containing a release of claims. On April 16, 2024, the Board of Directors of the Company designated Barbara Chan, the Company's Senior Vice President, Finance, as its principal financial officer and principal accounting officer, in each case effective on the Effective Date.

Ms. Chan, 60, has served as the Company's Senior Vice President, Finance since May 2020, and as of the Effective Date, will also serve as its Treasurer. Prior to that, Ms. Chan served as the Vice President of Finance and Chief Accounting Officer at Aegerion Pharmaceuticals, a therapeutics company, from June 2016 until December 2019. Ms. Chan has a B.S. and M.S. in Accounting and Taxation, respectively, from Bentley University.